- Home
- HKPD vs CMMB Comparison
HKPD vs CMMB Comparison
Compare HKPD & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKPD
- CMMB
- Stock Information
- Founded
- HKPD 2016
- CMMB 2004
- Country
- HKPD Hong Kong
- CMMB Israel
- Employees
- HKPD N/A
- CMMB N/A
- Industry
- HKPD Other Pharmaceuticals
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- HKPD Health Care
- CMMB Health Care
- Exchange
- HKPD Nasdaq
- CMMB Nasdaq
- Market Cap
- HKPD 20.9M
- CMMB 22.0M
- IPO Year
- HKPD 2025
- CMMB N/A
- Fundamental
- Price
- HKPD $1.32
- CMMB $1.09
- Analyst Decision
- HKPD
- CMMB Strong Buy
- Analyst Count
- HKPD 0
- CMMB 2
- Target Price
- HKPD N/A
- CMMB $8.50
- AVG Volume (30 Days)
- HKPD 161.5K
- CMMB 129.6K
- Earning Date
- HKPD 01-01-0001
- CMMB 08-20-2025
- Dividend Yield
- HKPD N/A
- CMMB N/A
- EPS Growth
- HKPD N/A
- CMMB N/A
- EPS
- HKPD 0.21
- CMMB N/A
- Revenue
- HKPD $20,770,344.00
- CMMB N/A
- Revenue This Year
- HKPD N/A
- CMMB N/A
- Revenue Next Year
- HKPD N/A
- CMMB N/A
- P/E Ratio
- HKPD $6.18
- CMMB N/A
- Revenue Growth
- HKPD 32.91
- CMMB N/A
- 52 Week Low
- HKPD $0.81
- CMMB $0.87
- 52 Week High
- HKPD $3.79
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- HKPD N/A
- CMMB 31.88
- Support Level
- HKPD N/A
- CMMB $1.07
- Resistance Level
- HKPD N/A
- CMMB $1.21
- Average True Range (ATR)
- HKPD 0.00
- CMMB 0.05
- MACD
- HKPD 0.00
- CMMB -0.00
- Stochastic Oscillator
- HKPD 0.00
- CMMB 12.50
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.